Alphatec Holdings (ATEC) saw its stock price drop sharply by 5% during intraday trading on Tuesday, reflecting investor concerns over recent developments.

The decline follows the company's announcement of an exclusive partnership with Theradaptive for OsteoAdapt, a spinal fusion bone graft. While the deal has potential, regulatory risks and execution challenges highlighted in the agreement may have spooked investors. Additionally, conflicting analyst sentiments on Alphatec's outlook further contributed to the sell-off, underscoring market uncertainty.